v3.26.1
LICENSE, COLLABORATION AND OTHER REVENUE (Tables)
 6 Months Ended
Jun. 30, 2026
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Schedule of Revenues Recognized from License, Collaboration and Other Significant Agreements
The Company recognized the following revenue from its license, collaboration and other revenue agreements (in thousands):
Three Months Ended June 30,Six Months Ended June 30,
EntityDescription2026202520262025
Medice
License and royalties related to the sale of Vafseo in the EU
$527 $16 $560 $24 
TPCLicense and Product Supply of Vafseo in Japan412 502 752 870 
JT and Torii License and royalties related to the sale of Riona in Japan1,424 1,493 2,603 2,662 
Total license and other revenue $2,363 $2,011 $3,915 $3,556 
Schedule of Changes in Contract Assets and Liabilities
The following tables present changes in the Company’s contract assets and liabilities related to the Company's sales to its AG Distributor (in thousands):
Six Months Ended June 30, 2026
Balance at
Beginning of
Period		AdditionsDeductionsBalance
at End
of Period
Contract assets:
Accounts receivable$194 $12,300 $(9,668)$2,826 
Contract liabilities:
Deferred revenue$2,681 $12,495 $(9,050)$6,126 
Six Months Ended June 30, 2025
Balance at
Beginning of
Period		AdditionsDeductionsBalance
at End
of Period
Contract assets:
Accounts receivable$— $8,662 $(3,294)$5,368 
Contract liabilities:
Deferred revenue$— $8,118 $(2,586)$5,532 
The Company recognized the following revenues related to the Company's sales to its AG Distributor as a result of changes in the contract asset and contract liability balances in the respective periods (in thousands): 
Three Months Ended June 30,Six Months Ended June 30,
Revenue Recognized in the Period:2026202520262025
Deferred revenue — beginning of the period
$5,616 $1,241 $8,626 $— 
The following tables present changes in the Company’s contract assets and liabilities related to license and other revenue (in thousands):
Six Months Ended June 30, 2026
Balance at
Beginning of
Period		AdditionsDeductionsBalance
at End
of Period
Contract asset:
Accounts receivable(1)
$2,391 $3,948 $(3,792)$2,547 
Contract liability:
Deferred revenue
$— $44 $— $44 
Six Months Ended June 30, 2025
Balance at
Beginning of
Period		AdditionsDeductionsBalance
at End
of Period
Contract assets:
Accounts receivable(1)
$2,010 $3,556 $(3,521)$2,045 
(1) Excludes accounts receivable related to amounts due to the Company from product sales of Auryxia and Vafseo which are included in the accompanying unaudited condensed consolidated balance sheets as of June 30, 2026 and 2025.
Schedule of Revenue Recognized Resulting from Changes in Contract Assets and Contract Liabilities
The Company recognized the following revenues as a result of changes in the contract asset and contract liability balances in the respective periods (in thousands): 
Three Months Ended June 30,Six Months Ended June 30,
Revenue Recognized in the Period:2026202520262025
Deferred revenue — beginning of the period$— $— $— $—